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REVIEW
The search was focused on the following areas of interest 
concerning RT patients: surgical complications, urologic ma-
lignancies, LUTS, graft lithiasis and andrological dysfunctions. 
The PubMed databases were searched using the following 
keywords: ‘kidney transplant’, ‘renal transplant’, and associ-
ated with ‘erectile dysfunction’, ‘male infertility’, ‘azoosper-
mia’, ‘surgical complications’, ‘urological neoplasm’, ‘graft 
lithiasis’, ‘transplant nephrectomy’ and ‘lower urinary tract 
symptoms’. All identified articles were examined by the au-
thors, and the most relevant articles were selected according 
to their level of evidence, as reported by Phyllips et al (2). Fur-
ther text searches were performed by separately adding the 
following keywords: ‘diagnosis’, ‘management’ and ‘therapy’. 
Evidence synthesis is herein reported.
Evidence synthesis
Post-RT surgical urological complications
The most common surgical urological complications include 
ureteral stricture and urinary leakage.
Ureteral strictures are generally classified as early (<3 
months from RT) and late-onset (>3 months). The former 
may be caused by kinking, temporary oedema of the ure-
teral wall, narrow anastomosis or extrinsic compression by 
haematoma or lymphocele (3, 4). The latter are usually re-
lated to bad ureteral vascularisation resulting in ischemia 
and subsequent fibrosis and three risk factors have been 
identified: donor age more than 65 years, kidneys with 
more than two arteries and delayed graft function (5). An-
other cause of late-onset ureteral stenosis but with differ-
ent pathogenesis is represented by BK virus (BKV) infection. 
This DNA virus acts as a pathogen only in immunocompro-
mised population. Urothelial cells are natural reservoirs for 
BKV replication and ureteral stenosis associated with this 
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Introduction and objectives
Renal transplant (RT) is the treatment of choice for end-
stage renal disease (ESRD), and the best option for patients qual-
ity of life. RT patients in the majority of cases have undergone 
many years of dialysis because of ESRD, with a lot of possible 
urological consequences mainly in terms of infertility, sexual, 
and lower urinary tract dysfunction. Furthermore, RT patients 
need prolonged immunosuppressant treatment, carrying itself 
a risk of infections and neoplastic diseases (1). Moreover, RT 
is not free from specific urological complications that might fi-
nally lead to allograft nephrectomy (AN). Taking all these things 
into consideration, a careful urological follow-up is advised for 
RT patients. The aim of the present review is to focus on the 
most relevant aspects of urological interest in RT patients, and 
particularly on surgical urological complications and their pos-
sible therapeutic solutions comprising transplant nephrectomy, 
urological de-novo malignancies, lower urinary tract symptoms 
(LUTS), graft lithiasis, and andrological dysfunctions.
Evidence acquisition
A literature search was conducted according to current 
methodological recommendations for systematic reviews (2). 
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virus accounts for 2-6% of all cases. Histologically, the ste-
notic tract appears ischaemic and fibrotic, resembling the 
lack of vascularisation encountered in bad vascular supply 
cases (6). Ureteral strictures may be treated with an en-
dourologic (usually percutaneous) or a surgical approach. 
Balloon dilation and temporary ureteral stenting are the 
most common endourologic procedures. Generally, percu-
taneous approach is considered as the first option, as it is 
simpler and has both a diagnostic and therapeutic value (7). 
In the short term, endourologic procedures have a high suc-
cess rate (from 73 to 100%), dropping to 40-55% in the long-
term due to a high recurrence rate (8-11). In 2005, Juaneda 
et al identified early obstruction and the presence of previ-
ous acute rejection as factors associated with better success 
rates (7). In the algorithm proposed by Helfand, a stricture 
less than 3 cm in length was considered as a good prognos-
tic factor (12). Recently, He et al proposed a new classifica-
tion on the basis of the entity and nature of the stricture. 
Specific treatments correspond to different grades of stric-
tures: temporary stent placement for G1 (increased cre-
atinine and hydronephrosis without evidence of significant 
stricture), balloon dilation or endoscopic incision for G2 
(stricture <1 cm), and immediate surgery for G3 (stricture 
>1 cm) (13). Ho:YAG laser endoureterotomy of the stenotic 
tract has a high success rate (>80%) in case of strictures less 
than 0.5-1 cm (14, 15). Surgery provides the highest success 
rate (>75%) (12, 16, 17). According to algorithms proposed 
by Helfand and He, surgery might be indicated after failure 
of endourologic treatment or as immediate treatment in 
case of late-onset strictures more than 3 cm (12, 13). The 
feasibility of a so-called extra-anatomic stent has been re-
cently described as a salvage procedure when surgery is not 
indicated or ineffective (18).
Urinary leakage occurring within 15 days from RT is usually 
due to anastomosis dehiscence, whereas ureteral necrosis ow-
ing to vascular insufficiency is the main cause of later events 
(19, 20). Donor age and delayed graft function have been iden-
tified as independent risk factors for ureteral leakage (5). To 
avoid this complication, a careful preservation of ureteral vas-
cularisation both during organ procurement and transplanta-
tion is mandatory (19). The endourologic management consists 
in temporary ureteral stenting or nephrostomy, even though it 
is not as effective as in strictures. Specific factors have been re-
lated to better treatment outcome, such as the occurrence of 
leakage more than 3 days after RT and a small entity of leakage, 
allowing the passage of contrast into the bladder at the first 
pyelography. According to recent studies, success rate of ure-
teral stenting for leakage ranges between 36 and 85% (21-23). 
In case of failure of endourologic treatment and in proximal or 
massive leakage, surgery is the only option (24, 25).
When surgical intervention is indicated, two options are 
available to manage leakages or stenosis: ureteral reimplan-
tation or reconstruction with native urinary tract. Ureteral 
reimplantation is indicated in case of anastomotic or distal 
defects. The most used surgical techniques reported in lit-
erature are Lich-Gregoire, Taguchi, and Politano-Ledbetter 
reimplantation. Tagichi reimplantation, therefore, is associ-
ated with more haematuria episodes, while Lich–Gregoire 
technique is the preferred one, as it is a relatively easy 
procedure, it does not require a second cistotomy such as 
Politano-Ledbetter reimplantation, and it requires less ure-
teral length compared with other techniques (26, 27). Pike 
et al described 18 strictures corrected with direct reimplan-
tation (occasionally requiring mobilisation of the urinary 
bladder) and 19 with reimplantation on a Boari flap, with 
a graft survival of 72.5% at 5 years (28). In a large series by 
Karam et al, reimplantation had no impact on graft survival 
as compared with non-stenotic grafts (10-year graft survival, 
64 vs. 63%, p = 0.36) (5). Native urinary tract can be used 
to perform uretero-ureterostomy (UU), pyelo-ureterostomy 
(PU) and, less frequently, pyelo-pyelostomy (PP), with ac-
ceptable success rates (76-100%) considering that only 
small series have been reported (24, 29-31).
Allograft nephrectomy
Nowadays, graft failure rates are declining due to an im-
provement in immnosuppressive regimens. Nevertheless, 
acute or chronic rejection of allograft still happens and repre-
sents an indication to AN. Other indications are represented 
by vascular complications, including thrombosis, infectious 
complications and neoplastic diseases (32). AN is considered 
as early if performed within 12 months from RT and late if 
performed afterwards (33). Late AN represents a challenging 
procedure due to the desmoplastic reaction of the graft on 
chronic rejection that makes it adherent to the abdominal 
wall. As a consequence, late AN might harbour more peri- 
operative complications than early ones, such as major bleed-
ings and death (32). When performing an AN, two major 
techniques are possible: intracapsular AN (ICAN) and extra-
capsular AN (ECAN). ICAN is performed by means of previous 
skin incision, graft identification, subsequent capsulotomy 
and finding of the plane between kidney parenchyma and 
renal capsule that is subsequently developed digitally until 
identification of the hilum that is closed with a vascular clamp 
and sutured with a two-line running suture. On the contrary, 
ECAN considers the complete and precise identification of 
vascular structures: artery and vein, and ureteral dissection 
until the bladder anastomosis. Subsequently, the structures 
are all ligated separately and AN is performed. As a matter 
of fact, the main difference between the two techniques is 
that ICAN leaves more donor tissues inside the recipient than 
ECAN, this possibly being a cause for allosensitisation and a 
reduced success of further transplantations. Literature find-
ings on this topic are inhomogeneous. Touma et al in a re-
cent study comparing ICAN with ECAN demonstrated a higher 
complication rate in the ECAN group in terms of perioperative 
bleeding and mortality (34). On the contrary, Mazzucchi et al 
did not find any statistically significant difference between 
the two techniques (32). Despite that, the only pathology 
that makes ECAN mandatory is graft neoplasia that forces sur-
geons to remove the entire graft for oncologic reasons. Inde-
pendently from kidney neoplasm, further studies are needed 
to compare the two techniques to establish which is the less 
morbid.
Urologic de-novo malignancies following RT
RT patients have an increased risk of developing neo-
plastic diseases (35), mainly due to immunosuppressive 
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treatment. This is the main risk factor for both short and 
long-term neoplasms, even though not every cancer type 
has the same etiopathogenetic association with immuno-
suppression (36). Among the mechanisms by which im-
munosuppressive treatment may favour malignancies are 
impaired immune surveillance and infections by oncogenic 
viruses. Irrespective of the causes, malignancy is the third 
cause of death in RT recipients following cardiovascular dis-
eases and infections.
De-novo cancer is a major complication of RT that causes 
significant short and long-term mortality. It accounts for 20% 
of RT patient deaths every year and 30% of deaths among RT 
recipients with a follow-up greater than 20 years (37). Accord-
ing to the main registries on this topic, which are the Cincinnati 
Transplant Tumor Registry (CTTR), the Nordic Renal Transplant 
Registry (NRTR) and the Australian and New Zeland Transplant 
Registry (ANTR), the most frequent de-novo neoplasms follow-
ing RT are skin cancer and posttransplant lymphoproliferative 
disease (PTLD). De-novo cancer incidence in patients followed-
up more than 20 years is between 34 and 50% and, of these, 
75% are skin cancers (38).
Focusing on urological malignancies, renal cell carcinoma 
(RCC) is the most frequent neoplasm accounting for almost 
31% of all urologic malignancies and for 3.3% of post-RT overall 
malignancies. RCC most frequently arises in native kidneys. A 
well-known risk factor is represented by developing acquired 
cystic kidney disease (ACKD), a condition that progressively in-
creases with the duration of chronic kidney disease and time 
on dialysis. Moreover, data also suggest that an unexpected 
underlying nephropathy, a uremic state, dialysis time and 
transplantation itself might have a role in malignant transfor-
mation of native kidneys (39). Nine cases have been reported 
in one of the largest series reported in literature, showing a 
15-fold increased risk of developing RCC compared with gen-
eral population (40).
According to Penn et al, the majority of kidney cancer 
is diagnosed early after RT, maybe due to more intense im-
munosuppression, while graft involvement is a rare event 
that requires every effort to spare the graft itself. Breda et al 
recently performed a retrospective study comparing patho-
logic characteristics of RCC arising in ESRD patients (under 
dialysis or after transplantation) with general population. 
Their results highlighted how RCC arising in ESRD patients 
harbour less aggressive characteristics, being much small-
er, lower grade and lower stage tumours, thus leading to a 
5-year cancer-specific survival of 90% compared with 69% of 
general population (41).
When feasible, conservative surgery represents the first 
choice in this case. There are also a few case reports of graft 
RCC treated with cryoablation or other minimally invasive 
techniques (42). Radical nephrectomy is indicated for RCC 
affecting native kidney irrespectively of its stage and grade. 
Concerning immunosuppressive regimen, the introduction of 
mammalian target of Rapamicin (mTOR) inhibitors, because 
of their well-known anti-proliferative activity, is highly sug-
gested even if not already standardised (43).
As for bladder tumours, the most frequent pathological 
pattern is transitional cell carcinoma (TCC), with a three-fold 
risk compared with the general population. Overall incidence 
of TCC in RT population is 0.4%. The relative risk (RR) of TCC 
in RT recipients is very high in China, as compared with west-
ern countries (RR 14 vs. 2), probably due to the consumption 
of aristolochic acid and rhubarb, which are known TCC risk 
factors and are widely used in Chinese traditional medicine 
(44). Moreover, in the Asian population, there is a trend to-
wards higher incidence of upper urinary tract involvement as-
sociated with higher-grade initial presentation in RT patients 
compared with dialysed ones. Zhang et al, in a single-centre 
retrospective study, confirm these data but no statistically sig-
nificant differences in overall and cancer-specific survival are 
reported from the authors between the two populations (45). 
Recognised risk factors are represented by age, time from 
transplantation, female sex and smoking history (46, 47).
Generally, TCC treatment does not differ from normal 
clinical practice. Concerns about the use of intravesical BCG 
are related to the risk of sepsis and the possible reduced ef-
ficacy in immunocompromised patients. However, a recent 
study evaluating BCG use in RT patients with high-risk TCC did 
not report any side effect or a decrease in its efficacy. Further 
studies are needed to confirm these data (46). Another differ-
ence in treating TCC is radical cystectomy. Pelvic lymph node 
dissection is a mandatory step of the procedure that is not 
usually performed in RT patients on the graft side, mainly due 
to the fibrosis that surrounds the graft and the risk of vascular 
damages to the graft itself.
Prostate cancer (Pca) is the most frequent urologic malig-
nancy in RT population with a two to five-fold greater risk than 
normal population (48). As far as immunosuppressive treat-
ment alters host response to oncogenic stimuli, it is worldwide 
accepted that active surveillance is not a considerable option 
for RT patients who develop de-novo PCa. These patients are 
therefore treated with radical prostatectomy (RP) or radiation 
therapy. Concerning surgical strategy, no difference has been 
found between different approaches in terms of oncologic or 
functional outcomes: open retropubic, laparoscopic/robotic 
transperitoneal and transperineal RP (49). In a cohort study 
on retropubic RP, Lechevallier et al evidenced some surgical 
difficulties that might be encountered in RT recipients. First 
of all, caution is needed when placing the retractors in order 
to avoid ureteral or graft damage. Furthermore, it is almost 
always impossible to perform lymph node dissection on the 
side of the graft, as previously described for cystectomy. 
Finally, careful identification and dissection of the ureter of 
the graft is needed to avoid injuries (50).
Lower urinary tract dysfunction related to RT
Assessment of lower urinary tract function in future RT re-
cipients is mandatory. This population can be divided into two 
groups: patients with a conserved diuresis and patients with 
disused bladders due to oliguria or complete anuria. The for-
mer needs to be evaluated with standard LUTS questionnaires, 
uroflowmetry and ultrasound with assessment of post-void re-
sidual volume, in order to rule out any bladder outlet obstruc-
tion or other less frequent conditions that could lead to graft 
damage (51). The latter needs careful evaluation because of 
an increased risk of developing filling phase LUTS after RT. Pro-
gressive reduction in bladder capacity and compliance is nor-
mally found in patients with ESRD due to an oliguric and then 
a progressively anuric state. Profound anatomic changes occur 
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in disused bladder that leads to the development of a small 
and relatively poorly compliant bladder wall. In a comparative 
study, Chun et al analysed a population of 340 patients with 
ESRD demonstrating a linear and progressive relation between 
total dialysis years and both bladder capacity and compliance 
(52). Reduced bladder capacity and compliance may be respon-
sible for the development of posttransplant LUTS, high-pressure 
bladder contraction and possibly graft damage. Careful evalua-
tion of bladder function with urodynamic exam is therefore ad-
visable before RT. The same authors showed that patients with 
bladder capacity inferior to 100 ml had a higher risk of develop-
ing LUTS because bladder function most likely will not recover 
completely. Lefrancois et al (53), on the contrary, demonstrated 
that the majority of patients recover bladder capacity, contrac-
tility and function after RT. These findings were confirmed by 
Serrano et al, who performed urodynamic examination in pre-
viously anuric patients and demonstrated that bladder capacity 
reached normal values (300 ml) after RT even in patients with 
a bladder capacity inferior to 100 ml before RT (54). Other au-
thors confirmed a progressive improvement of LUTS even at 
6 years after RT (55). These findings question the need to per-
form a bladder augmentation before RT with the aim of obtain-
ing a low bladder filling pressure and an adequate cistometric 
capacity. Morales et al evaluated the possibility of performing 
RT in patients with augmented bladder, showing that urinary 
tract infections (UTIs) due to excessive postvoid residue repre-
sented the principal complication. They concluded that RT in 
an augmented bladder is feasible both before and after RT, but 
there might be the need of a period of clean intermittent cath-
eterisation to minimise the risk of UTIs (56).
Graft urolithiasis
Urinary stones in RT patients are a rare complication, with 
a posttransplant incidence inferior to 2% (57-59). Only case re-
ports and small series (<35 patients) described this event and 
its management. Renal stones may also be found already in the 
graft at procurement (so-called ‘donor-gifted’). Asymptomatic 
renal stones were found in 19 (5%) cases out of 377 potential 
living donors evaluated with CT scan by Olsburgh et al (60) and 
do not represent contraindication to RT but lead to a potential 
risk of severe postoperative complications. Treatment is indi-
cated and most recent studies support ex-vivo ureterorenosco-
py. Schade et al described 18 cases treated on bench by direct 
basket extraction or laser lithotripsy; all the recipients were 
stone-free at long-term follow-up (61). Similar results were 
reported by other studies, without any intra or postoperative 
complication, also in case of multiple stones (60, 62).
Post-transplant lithiasis can be found occasionally during 
follow-up. In case of ureteral migration, clinical presentation 
can be different as compared with general population: patients 
may report no pain because of graft denervations (57) and may 
present with urinary infections, haematuria and graft function 
impairment (57, 59). In other cases, clinical presentation may 
be dramatic with acute renal injury and sepsis (63), requiring 
immediate nephrostomy (63, 64). Elective treatments consist in 
conservative management, extracorporeal shockwave lithotrip-
sy (ESWL), ureteroscopy, percutaneous nephrolithotomy and 
open surgery. Stones smaller than 4 mm can be safely managed 
by close surveillance alone, as they tend to remain stable or 
pass spontaneously without complications (65). ESWL is feasi-
ble in RT patients, even if stone targeting can be difficult due to 
the overlying bony pelvis. Prone position can counter this disad-
vantage. Challacombe et al successfully performed 13 ESWLs in 
a prone position (66), while in other series, a success rate more 
than 70% was reported without any complication (57, 64, 67). 
Cassini et al concluded that ESWL could be safely performed in 
case of stones less than 15 mm, while other treatments may 
be considered in case of failure (57). Ureteroscopy is also effec-
tive for stones less than 15 mm, with direct basket extraction 
or Holmium laser lithotripsy. Both anterograde and retrograde 
approaches have been described (68). Retrograde ureteroscopy 
can be challenging due to the location and the mobility of reim-
planted ureteral orifice. Most studies reported success rates of 
60-80% (58, 65, 69). Hyams et al described seven successful ret-
rograde ureteroscopy and recommended the use of a Kumpe 
catheter to facilitate the access to ureteral orifice (68). In case 
of stones larger than 15-20 mm, PCNL is the non-surgical treat-
ment with the highest stone-free rate (66). Krambeck et al pre-
sented one of the largest series of PCNL in RT patients, using a 
standard technique and dilating the existing nephrosotmy tract 
with Amplatz fascial dilators till 28Fr. Stone-free rate was 76%, 
but after a second procedure, all patients became stone-free 
(70). Mini-percutaneous nephrolithotomy using a 8.5/11.5 F 
nephroscope was successfully described by He in 2007 in seven 
patients (71). Open surgery is still a valid option in most com-
plex cases, especially when stones coexist with ureteral stric-
tures, or after failure of minimally invasive procedures. Stone 
surgery in RT patients is challenging due to the high risk of vas-
cular damage and systemic complications (63). In the largest 
series of renal graft stones reported by Verrier et al, eight out 
of 31 patients required open surgery to remove the stone and 
correct a concomitant ureteral stricture (65).
Andrological dysfunctions related to RT
End-stage renal disease affects patients’ sexual and repro-
ductive functions. As a matter of fact, erectile dysfunction (ED), 
loss of libido and infertility are frequently reported. Even if part 
of these problems can be restored after RT, sexual and repro-
ductive troubles are common complaints in these patients 
(72-74). Thus urologists dealing with RT have to be familiar 
with diagnosis and treatment of andrological complaints.
Sexual function
Sexual function is a main aspect in everyday life of men. It 
has been widely demonstrated that an impairment in sexual 
function significantly leads to a decrease in the quality of life, 
and the same has been confirmed both in ESRD patients and 
RT recipients. Therefore, an adequate sexual function repre-
sents an important aspect and needs to be perceived in RT 
patients (75, 76). ESRD is frequently associated with sexual 
dysfunction and mainly with ED. Several factors have been 
considered as a risk factor to ED such as hormonal alteration, 
side effects of drugs, vascular interference or concomitant pa-
thology such as diabetes mellitus and hypertension (77, 78). 
RT role in restoring a normal sexual function is still controver-
sial and only few studies have clearly underlined the beneficial 
effects of RT on the erectile function (79-82).
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The prevalence of ED remains elevated even after trans-
plantation (83-85). Sparse studies have revealed the possible 
negative effect of the graft arterial anastomosis on the arte-
rial inflow of the penis, both in case of internal and external 
iliac anastomosis. Even if a strict connection between hae-
modynamic changes and RT has been well demonstrated, the 
direct relation with ED needs to be confirmed in prospective, 
randomised controlled studies (86, 87). RT recipients, indeed, 
often have other comorbidities, which might affect erectile 
function and represent a disturbing confounder in the rela-
tionship between RT and ED.
In case of ED, after a standard hormonal screening, RT 
recipients can be safely treated with Phosfodiesterase-5 inhibi-
tors (PDE5-I) with excellent results in terms of erectile function 
recovery and low rate of adverse effect according to EAU guide-
lines (88, 89). In selected patients refractory to medical treat-
ment, a penile prosthesis implantation can be proposed, even 
if a slightly higher rate of complication has to be considered 
(90). RT recipients, considering the previous pelvic surgery, 
can benefit from an ectopic reservoir placement between the 
transversalis fascia and the rectus muscle, in order to prevent 
possible complications related to a classical prevescical place-
ment (91).
Reproductive function
It is widely accepted that ESRD is associated with im-
paired spermatogenesis and testicular damage. Main factors 
responsible are secondary to uremia in terms of hormonal, 
vascular and neuronal impairments (92, 93).
Moreover, as reported in the previous paragraph, the re-
productive function can be affected as a consequence of sexual 
dysfunction. Even if RT represents the most effective solution 
to significantly improve the reproductive function, an increase 
in sperm count is reported in only half of RT patients. The fac-
tors, which negatively affect the possibility of recovering a nor-
mal reproductive function, are Folliculo-stimulating hormone 
(FSH) level before transplantation, a prolonged ESRD and 
previous dialysis (94). Probably, the main factor responsible 
affecting the reproductive function in transplanted patients 
is the use of immunosuppressive agents, which many studies 
suggest to be potentially gonadotoxic (95). Among the immu-
nosuppressive agents used in RT recipients, few studies have 
underlined the potential gonadotoxic role of cyclosporine both 
in experimental models and in humans (96, 97), while sirolimus 
is well known to impair spermatogenesis. In the literature, few 
reports exist of azoospermic patients treated with sirolimus in 
which a complete restore of the spermatogenesis was reached 
after replacing sirolimus with tacrolimus (98).
However, if azoospermia is confirmed in two consecutive 
sperm analyses, a standard TeSE can be considered. No pe-
culiar contraindications to TeSE are reported in RT recipients. 
Recently, the first case of a successful intracistoplasmatic in-
jection of spermatozoa (ICSI) in an azoospermic and RT man 
has been described (99).
Conclusion
Renal transplantation is the treatment of choice for ESRD. 
Many surgical complications and clinical problems related to 
RT represent a possible diagnostic and therapeutic challenge 
for the urologist.
Ureteral stenosis and urinary leakage represent the main 
surgical complications needing urologic care. The treatment 
of ureteral stenosis is mainly decided according to its sever-
ity. Surgery, especially ureteroneocistostomy, is the most 
effective treatment, but endourologic balloon dilatation or 
endoureterotomy represent the first option in case of short 
stenosis with the aim of reducing invasiveness. Surgery is 
therefore reserved to recurrent or severe stenosis and may 
involve the use of native excretory system. Urinary leakage is 
treated, according to its entity, with prolonged stenting and, 
if persistent or massive, with the same surgical interven-
tions described for ureteral stenosis. AN is a surgical hazard-
ous procedure that is needed when graft fails for whatever 
reason and that could be performed with either the intra or 
extracapsular way. Intracapsular AN seems to harbour less 
complication rate but might have the disadvantage of allo-
sensitisation due to the fact that donor kidney capsule and 
ureter are left in situ.
Regarding de-novo urologic malignancies, RCC of native 
kidneys is the most frequent and it is best managed with 
radical nephrectomy irrespectively of neoplasm size. Neph-
ron-sparing surgery is the treatment of choice for RCC of the 
graft with the aim of preserving the graft. TCC is relatively 
rare but seems to be more aggressive in immunosuppressed 
patients. For this reason, high-risk patients might probably 
benefit from an early aggressive radical treatment, such as 
radical cystectomy. Pca represents another possible thera-
peutic challenge mainly due to possible surgical difficulties. 
Active surveillance is usually not considered an option for RT 
recipients. Different surgical approaches to RP are consid-
ered effective. Transperineal RP may be used to reduce the 
risk of graft lesion, but it does not allow performing lymph 
node dissection.
RT recipients are at an increased risk of developing post-
RT LUTS due to reduced bladder capacity and contractility dis-
orders. After RT, bladder retraining leads to the progressive 
recovery of its function and there are evidences that even 
after more than 6 months, LUTS may improve. In more severe 
cases, bladder augmentation before or after RT may be per-
formed with acceptable long-term results.
Graft lithiasis is a rare RT complication. All treatment op-
tions, including SWL, ureterorenoscopy and PCNL, have high 
success rates and are chosen according to stone size and site. 
It must be taken into account that the lack of graft innervation 
can make renal colic totally asymptomatic in RT patients with 
urinary stones and acute renal insufficiency can be the first 
manifestation.
Sexual dysfunction is common in RT patients due to ESRD 
first and immunosuppressive treatment afterwards. Initial 
treatment with PDE5 inhibitors and, in case of failure, pros-
thesis implant represent the standards of care. According 
to fertility, azoospermia mainly due to immunosuppressive 
treatment has been reported. TeSE and ICSI proved to have 
promising results in these cases.
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